SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer
Authors
Keywords
Uterine cancer, Metastasis, Cancer chemotherapy, Gene expression, Small interfering RNAs, Cancer treatment, Endometrial carcinoma, Polymerase chain reaction
Journal
PLoS One
Volume 10, Issue 9, Pages e0138515
Publisher
Public Library of Science (PLoS)
Online
2015-09-26
DOI
10.1371/journal.pone.0138515
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance
- (2013) Timo Hupfeld et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer
- (2013) Yoshimichi Tanaka et al. CANCER BIOLOGY & THERAPY
- Sal-like 4(SALL4) suppressesCDH1expression and maintains cell dispersion in basal-like breast cancer
- (2013) Junji Itou et al. FEBS LETTERS
- Oncofetal Gene SALL4 in Aggressive Hepatocellular Carcinoma
- (2013) Kol Jia Yong et al. NEW ENGLAND JOURNAL OF MEDICINE
- The EMT signaling pathways in endometrial carcinoma
- (2012) Eva Colas et al. Clinical & Translational Oncology
- Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers
- (2012) Tsunekazu Oikawa et al. HEPATOLOGY
- Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma
- (2012) Agnes Y. Bahng et al. Journal of Gynecologic Oncology
- SALL4 is a robust stimulator for the expansion of hematopoietic stem cells
- (2011) J. R. Aguila et al. BLOOD
- c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells
- (2011) A. Porro et al. MOLECULAR CANCER RESEARCH
- SALL4, a Stem Cell Factor, Affects the Side Population by Regulation of the ATP-Binding Cassette Drug Transport Genes
- (2011) Ha-Won Jeong et al. PLoS One
- Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells
- (2010) Kyoung Bin Cho et al. CANCER LETTERS
- Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells
- (2010) Antonio Porro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Differential Roles of Sall4 Isoforms in Embryonic Stem Cell Pluripotency
- (2010) S. Rao et al. MOLECULAR AND CELLULAR BIOLOGY
- A Novel SALL4/OCT4 Transcriptional Feedback Network for Pluripotency of Embryonic Stem Cells
- (2010) Jianchang Yang et al. PLoS One
- SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors
- (2009) Dengfeng Cao et al. CANCER
- Depletion of Embryonic Stem Cell Signature by Histone Deacetylase Inhibitor in NCCIT Cells: Involvement of Nanog Suppression
- (2009) J. S. You et al. CANCER RESEARCH
- Development and Cancer: At the Crossroads of Nodal and Notch Signaling
- (2009) L. Strizzi et al. CANCER RESEARCH
- ABCG2: A perspective
- (2008) Robert W. Robey et al. ADVANCED DRUG DELIVERY REVIEWS
- SALL4 is a key regulator of survival and apoptosis in human leukemic cells
- (2008) J. Yang et al. BLOOD
- Mechanisms of malignant progression
- (2008) R. A. Weinberg CARCINOGENESIS
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started